Cervical Dystonia Clinical Trial
Official title:
Optimizing tDCS in Cervical Dystonia
Dystonia is a devastating disorder defined by involuntary, sustained muscle contractions or
abnormal postures that can affect any part of the body. Cervical dystonia (CD) is the most
pervasive form of dystonia affecting 60-90,000 individuals in the United States alone and is
characterized by involuntary twisting of the neck. The symptoms of CD are disabling,
disfiguring, painful, and have a strongly negative impact on quality of life, including
social withdrawal and depression. At present, there is no treatment that has been shown to
have long term benefit in CD. Standard of care (SOC) is botulinum toxin, which temporarily
paralyzes affected muscles, resulting in reduced muscle spasms. This treatment has many
undesirable side effects, variable effectiveness, is expensive, and must be repeated every 3
months throughout the lifespan. Physical therapy based treatments aimed at retraining posture
or stretching dystonic muscles are largely ineffective and not typically delivered as a part
of standard of care. There is an urgent need for novel and effective therapies. Emerging
technologies, specifically non-invasive brain stimulation (NBS), have demonstrated compelling
evidence to make a meaningful impact in the lives of people with CD. In this study,
individuals with cervical dystonia will be randomly assigned to receive tDCS for 15 minutes
daily for 4 days in 1 of 4 stimulation location groups.
Hypothesis 1: One location of stimulation will result in clear benefit with at least 1
standard deviation (SD) improvement in the CDQ-24, the primary outcome measure, at 1-week
follow-up.
Hypothesis 2: The cortical silent period will be the most sensitive measure investigated and
will demonstrate significant increase in inhibition as determined by an elongation of silent
period in the affected upper trapezius muscle.
Hypothesis 3: The stimulation location determined to be most effective in Objective 1 will
produce the greatest physiologic change in inhibition increase.
Hypothesis 4: The hypothesis for this aim is if certain characteristics can predict response
to treatment, a strong association will be seen between baseline measure(s) and the primary
outcome measure. A thorough assessment of characteristics including: age, sex, duration of
symptoms, genotyping for two specific polymorphisms, botulinum toxin history, baseline
measures of outcome variables, measures of brain excitability, and genetic testing will
predict response.
Study Purpose
This study will investigate the use of an experimental research device called transcranial
direct current stimulation (tDCS). tDCS is a way to stimulate the brain with potential
therapeutic benefits. It works by either increasing or decreasing brain excitability. This is
done by delivering a current to the outside of the head. This weak electrical current then
passes through the skull and modulates the underlying brain tissue. Genetic factors may
contribute to the effectiveness of this intervention; therefore, a saliva sample will be
collected to assess the status of two genes: Brain derived neurotrophic factor (BDNF) and
apolipoprotein E4. Our purpose is to determine the best location of stimulation for tDCS that
improves the symptoms and quality of life in people with CD. The results of this study will
help to identify alternative interventions for people with cervical dystonia. Brain
excitability will be measured using an additional form of non-invasive brain stimulation,
specifically by a device called a transcranial magnetic stimulator. By applying a magnetic
field to the outside of the head, electrical currents are produced within the brain that can
transiently affect brain activity and be recorded though electrodes on your skin. Using this
procedure, different areas of the brain can be studied to gain a greater understanding of the
brain physiology in patients with cervical dystonia.
Procedures
Intervention: Briefly, non-invasive brain stimulation can be delivered safely and painlessly
via different mechanisms with the goal of either exciting or inhibiting the underlying brain
issue. In focal dystonia, as indicated above, there is thought to be a lack of inhibition,
thus settings are typically used to increase inhibition. Transcranial direct current
stimulation (tDCS) is one device that has been shown to be safe and effective at modulating
excitation and inhibition in humans and has been used extensively in a variety of research
applications for over 10 years. In addition to the potential physiologic benefit of altering
excitability, tDCS is a particularly practical technique for use in people with CD, because
it does not require one's head to remain still, thus not applying additional stress to the
impaired neck.
An investigator will deliver tDCS using a constant current of 2 milliamps (mA) using a direct
current stimulator (TCT Research Limited, Hong Kong) via two 35 cm2 saline soaked sponge
electrodes. Treatment is 1x/day for 4 days. Electrode placement will be at one of four
locations referenced in terms of dystonic head-turn resting position (i.e. if head turns to
the left, the primary muscles involved are on the left, so contralateral M1 would be the
right hemisphere): 1) Bilateral M1 with cathode to contralateral M1 and anode to ipsilateral
M1, 15 minutes (Goal: decrease contralateral M1 excitability); 2) Cerebellum with anode to
ipsilateral cerebellum with cathode to ipsilateral side of face, 15 minutes (Goal: increase
ipsilateral cerebellum activation which exerts inhibitory effect on motor circuits); 3)
M1+cerebellum: M1 will first be 'primed' with anode on contralateral M1, cathode on face, for
10 min, followed immediately by 15 min of cerebellar stimulation as in #2. (Goal: prime the
contralateral M1 with increased excitability to engage a potentially larger effect from the
following ipsilateral cerebellar stimulation that will be excited to exert inhibitory effect
on the motor circuits including M1); or 4) Sham stimulation: electrode placement will be same
as M1. Sham tDCS will be applied by ramping down current intensity to 0 after 30 seconds
following standard practice for sham tDCS (Gandiga et al. 2006).
Pre-testing (Day1) will occur 10 weeks post standard care (SC) visit, so the participant will
be near most impaired level of functioning prior to 12 week visit for botulinum (BTX)
injection. tDCS will be delivered on day 1 and each subsequent day for 4 days. Posttesting
will occur on Day5 and then 1 week later prior to SC visit (follow up- day 12). The primary
endpoint of interest is follow up at one week.
Cortical Excitability Testing: Before and after intervention, single-pulse TMS will be
delivered with a figure of eight coil (90 mm wing diameter) (MagStim Co., Whitland, Dyfed,
Wales), positioned over M1. The 'hotspot' over the M1 contralateral to the direction of
dystonic head turn will be used to collect motor evoked potentials (MEPs) in cervical muscles
(upper trapezius) ipsilateral to head turn will be located and marked on the scalp. Various
measures will be collected according to established methods to assess cortical excitability
by single and paired pulse TMS.
Clinical assessment: Severity of CD will be assessed before and after the intervention.
Behavioral measures will be administered by an investigator, blinded to intervention and will
be assessed pre and post each intervention and at follow up. The primary endpoint of interest
is the Craniocervical Dystonia Questionnaire CDQ-24. This primary outcome was selected
because it is a patient-rated, disease-specific assessment of quality of life, which we feel
should be the primary issue of concern. Secondary measures are TWSTRS and visual analog
scale.
CDQ-24: The CDQ-24 contains 24 items with 5 subscales: stigma, emotional well-being, pain,
activities of daily living and social/family life. Internal consistency and reliability is
satisfactory for all sub-scales and total score with good sensitivity and high test/retest
reliability (Muller, 2004).
TWSTRS. Toronto Western Spasmodic Torticollis Rating Scale is an outcome measure used to rate
severity, disability and pain in CD (Consky et al., 1990). TWSTRS utilizes three sub-scores
of physician-based severity (0-35), patient-based disability (0-30) and pain (0-20) with
higher scores indicating greater severity of symptoms. Inter-observer reliability is
excellent (rs=99) and good for disability and pain measurements (r˃0.88). The global severity
scale was moderate (rs=0.63)(Salvia et al., 2006). TWSTRS exam will be videotaped for posthoc
assessment by investigator blinded to group and testing period.
Visual Analog Scale (VAS). At the end of each intervention session participants will be asked
to rate the ease of movement and perceived pain during cervical rotation in the contralateral
direction to their head turn using VAS for self-assessment.
Adverse reactions. Adverse reactions will be recorded using established reporting forms.
Genetic Testing: At the last session, a saliva sample will be collected for genetic screening
for BDNF and apolipoprotein E4 polymorphisms. We will collect approximately 2 ml (less than
one-half teaspoon) of saliva by asking the subject to spit into a tube. It may take up to 30
minutes to provide a saliva sample, however, most people typically require less time
(approximately 5 minutes). Collection of saliva using Oragene Discover is non-invasive and
there are no anticipated personal risks of injury.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03617367 -
Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)
|
Phase 3 | |
Not yet recruiting |
NCT04057911 -
A Trial of Non-invasive Stimulation in Cervical Dystonia
|
N/A | |
Completed |
NCT00541905 -
Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia
|
Phase 4 | |
Unknown status |
NCT00418925 -
Efficacy of Dronabinol for the Treatment of Cervical Dystonia
|
Phase 2 | |
Not yet recruiting |
NCT05715138 -
Comparison of Pallidal With Subthalamic Deep Brain Stimulation for Cervical Dystonia
|
N/A | |
Completed |
NCT02131467 -
Safety and Tolerability of Perampanel in Cervical Dystonia
|
Phase 1/Phase 2 | |
Completed |
NCT02959645 -
Assessment of Brain Activities in Cervical Dystonia
|
||
Completed |
NCT03805152 -
Abobotulinum Toxin and Neubotulinum Toxin Injection in Cerivical Dystonia
|
Phase 3 | |
Completed |
NCT04949594 -
Relief of Pain in Patients With Cervical Dystonia Through the Use of Transcutaneous Electric Nerve Stimulation (TENS)
|
||
Recruiting |
NCT01664013 -
The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients
|
Phase 4 | |
Completed |
NCT00447772 -
Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
|
Phase 3 | |
Completed |
NCT00210431 -
Post Marketing Surveillance Study of Dysport
|
||
Completed |
NCT05157100 -
Clinical Study of Ingrezza (Valbenazine) for the Treatment of Cervical Dystonia
|
Phase 4 | |
Completed |
NCT00257660 -
Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia
|
Phase 3 | |
Completed |
NCT05103202 -
Efficacy and Safety of 10-Week or Shorter vs 12-Week or Longer Injection Intervals of Botulinum Toxin
|
||
Terminated |
NCT00760318 -
Keppra for Cervical Dystonia
|
Phase 2 | |
Completed |
NCT00323765 -
Plasticity in Cervical Dystonia
|
N/A | |
Completed |
NCT04171258 -
Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Patients With Cervical Dystonia
|
Phase 1 | |
Completed |
NCT04849988 -
A Phase 2 Study to Evaluate the Safety and Efficacy of ABP-450 in the Treatment of Cervical Dystonia
|
Phase 2 | |
Completed |
NCT03471923 -
Non-Motor Features of Cervical Dystonia (CD)
|